Status:

COMPLETED

Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans

Lead Sponsor:

University of North Carolina, Chapel Hill

Collaborating Sponsors:

Environmental Protection Agency (EPA)

National Institute of Environmental Health Sciences (NIEHS)

Conditions:

Healthy Control

Eligibility:

All Genders

18-40 years

Phase:

NA

Brief Summary

The principal purpose of this study is to identify hyper-responsive, responsive and non-responsive groups of healthy human subjects based on their airway neutrophilic response to ozone exposure, and t...

Detailed Description

Sputum assessment day: Subjects meeting the required health status following the medical screening will be provided with a verbal and written description of all experimental procedures and possible ri...

Eligibility Criteria

Inclusion

  • Subjects will have an FEV1/FVC equal to or greater than 75%, as well as FVC and FEV1 greater than or equal to 80% of predicted normal for height and age.
  • Skin testing will be performed; subjects with active allergies will not be studied while they are symptomatic.
  • Subjects must be in good general health with no history of acute or chronic cardiovascular disease, chronic respiratory disease, and acute respiratory illness within 4 weeks, and without contraindications for performing sustained light to moderate exercise.
  • Subjects must demonstrate the ability to produce an acceptable induced sputum sample during the training session. If the sample is unsatisfactory, the subject's participation will end at this point.
  • Antidepressants and other medications may be permitted if in the opinion of the investigator the medication will not interfere with the study procedures or compromise safety; and if the dosage has been stable for 3 months.
  • Subjects must smoke less than 10 cigarettes (one half pack) a month for at least 3 years. Individuals who have smoked greater than 10 pack years lifetime will be excluded.
  • Subjects must be willing to refrain from strenuous physical activity for 24 hours before and after exposure.

Exclusion

  • asthmatic or active allergic rhinitis
  • Non English speaking volunteers will be excluded as no one on the study staff is fluent in other languages likely to be encountered.
  • use anti-inflammatory medications or medications for asthma

Key Trial Info

Start Date :

February 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 20 2017

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT00840528

Start Date

February 1 2002

End Date

June 20 2017

Last Update

September 25 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

US EPA Human Studies Facility

Chapel Hill, North Carolina, United States, 27514